Reni Benjamin
Stock Analyst at JMP Securities
(1.25)
# 3,557
Out of 4,918 analysts
172
Total ratings
35.46%
Success rate
-17.7%
Average return
Main Sectors:
Stocks Rated by Reni Benjamin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| INBX Inhibrx Biosciences | Reiterates: Market Perform | n/a | $21.89 | - | 10 | May 15, 2025 | |
| BCYC Bicycle Therapeutics | Maintains: Market Outperform | $26 → $22 | $8.04 | +173.80% | 14 | May 2, 2025 | |
| CUE Cue Biopharma | Reiterates: Market Outperform | $2 | $0.77 | +160.86% | 5 | Apr 2, 2025 | |
| BCAB BioAtla | Maintains: Market Outperform | $5 → $1 | $0.35 | +189.02% | 9 | Mar 31, 2025 | |
| ALLO Allogene Therapeutics | Upgrades: Market Outperform | $5 | $1.19 | +321.94% | 7 | Mar 14, 2025 | |
| INCY Incyte | Reiterates: Market Perform | n/a | $75.89 | - | 28 | Mar 11, 2025 | |
| ACET Adicet Bio | Reiterates: Market Perform | n/a | $0.68 | - | 5 | Mar 7, 2025 | |
| HOWL Werewolf Therapeutics | Maintains: Market Outperform | $12 → $4 | $1.22 | +227.87% | 5 | Jan 14, 2025 | |
| CGEN Compugen | Maintains: Market Outperform | $8 → $4 | $1.50 | +166.67% | 1 | Aug 8, 2022 | |
| ADVM Adverum Biotechnologies | Upgrades: Market Perform | n/a | $2.34 | - | 4 | Nov 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.18 | - | 2 | Dec 3, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Market Perform | n/a | $7.38 | - | 3 | Jun 14, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $16 | $0.08 | +20,952.63% | 1 | Oct 22, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $11 → $10 | $19.88 | -49.70% | 2 | Oct 12, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $5 | $3.95 | +26.74% | 6 | Jun 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $28 | $6.02 | +365.12% | 11 | Jun 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | n/a | $23.60 | - | 2 | Jun 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $40 | $28.21 | +41.79% | 4 | Jun 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | n/a | $1.40 | - | 7 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $2.75 | - | 11 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $4 | $0.85 | +370.59% | 5 | Apr 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $0.80 | - | 10 | Mar 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $7 → $8 | $8.41 | -4.88% | 1 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $60 | $49.24 | +21.85% | 1 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | n/a | $7.95 | - | 1 | Feb 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $315 | $225.96 | +39.41% | 1 | Feb 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | n/a | $88.02 | - | 1 | Feb 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $265 | $227.28 | +16.60% | 1 | Feb 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Outperform | $28 → $17 | $3.08 | +451.95% | 3 | Nov 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $0.33 | - | 3 | Nov 15, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | n/a | $8.23 | - | 4 | Jun 14, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Market Perform | n/a | $1.56 | - | 2 | Feb 7, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Outperform | $22 → $12 | $28.86 | -58.42% | 1 | Sep 25, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $19.59 | - | 1 | Nov 15, 2017 |
Inhibrx Biosciences
May 15, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $21.89
Upside: -
Bicycle Therapeutics
May 2, 2025
Maintains: Market Outperform
Price Target: $26 → $22
Current: $8.04
Upside: +173.80%
Cue Biopharma
Apr 2, 2025
Reiterates: Market Outperform
Price Target: $2
Current: $0.77
Upside: +160.86%
BioAtla
Mar 31, 2025
Maintains: Market Outperform
Price Target: $5 → $1
Current: $0.35
Upside: +189.02%
Allogene Therapeutics
Mar 14, 2025
Upgrades: Market Outperform
Price Target: $5
Current: $1.19
Upside: +321.94%
Incyte
Mar 11, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $75.89
Upside: -
Adicet Bio
Mar 7, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $0.68
Upside: -
Werewolf Therapeutics
Jan 14, 2025
Maintains: Market Outperform
Price Target: $12 → $4
Current: $1.22
Upside: +227.87%
Compugen
Aug 8, 2022
Maintains: Market Outperform
Price Target: $8 → $4
Current: $1.50
Upside: +166.67%
Adverum Biotechnologies
Nov 12, 2020
Upgrades: Market Perform
Price Target: n/a
Current: $2.34
Upside: -
Dec 3, 2019
Downgrades: Market Perform
Price Target: n/a
Current: $1.18
Upside: -
Jun 14, 2019
Reinstates: Market Perform
Price Target: n/a
Current: $7.38
Upside: -
Oct 22, 2018
Maintains: Outperform
Price Target: $20 → $16
Current: $0.08
Upside: +20,952.63%
Oct 12, 2018
Maintains: Outperform
Price Target: $11 → $10
Current: $19.88
Upside: -49.70%
Jun 24, 2025
Reiterates: Market Outperform
Price Target: $5
Current: $3.95
Upside: +26.74%
Jun 4, 2025
Reiterates: Market Outperform
Price Target: $28
Current: $6.02
Upside: +365.12%
Jun 2, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $23.60
Upside: -
Jun 2, 2025
Reiterates: Market Outperform
Price Target: $40
Current: $28.21
Upside: +41.79%
May 15, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $1.40
Upside: -
May 9, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $2.75
Upside: -
Apr 29, 2025
Reiterates: Market Outperform
Price Target: $4
Current: $0.85
Upside: +370.59%
Mar 14, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $0.80
Upside: -
Mar 12, 2025
Maintains: Market Outperform
Price Target: $7 → $8
Current: $8.41
Upside: -4.88%
Mar 3, 2025
Reiterates: Market Outperform
Price Target: $60
Current: $49.24
Upside: +21.85%
Feb 6, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $7.95
Upside: -
Feb 6, 2025
Reiterates: Market Outperform
Price Target: $315
Current: $225.96
Upside: +39.41%
Feb 6, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $88.02
Upside: -
Feb 6, 2025
Reiterates: Market Outperform
Price Target: $265
Current: $227.28
Upside: +16.60%
Nov 10, 2020
Downgrades: Outperform
Price Target: $28 → $17
Current: $3.08
Upside: +451.95%
Nov 15, 2019
Downgrades: Market Perform
Price Target: n/a
Current: $0.33
Upside: -
Jun 14, 2019
Reinstates: Outperform
Price Target: n/a
Current: $8.23
Upside: -
Feb 7, 2019
Upgrades: Market Perform
Price Target: n/a
Current: $1.56
Upside: -
Sep 25, 2018
Downgrades: Outperform
Price Target: $22 → $12
Current: $28.86
Upside: -58.42%
Nov 15, 2017
Downgrades: Market Perform
Price Target: n/a
Current: $19.59
Upside: -